Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy

Next Previous
Search
Trial Profile

KEYMAKER-U01 Substudy 3: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Anti-PD-(L)1 Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Boserolimab (Primary) ; MK 0482 (Primary) ; MK-4830 (Primary) ; Pembrolizumab (Primary) ; Diphenhydramine; Paracetamol
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-01C; MK-3475-01C/KEYMAKER-U01C
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 31 Oct 2022 Status changed from recruiting to active, no longer recruiting.
    • 21 Oct 2021 Status changed from active, no longer recruiting to recruiting.
    • 10 Jun 2021 Prtocol amended with addition of new drug regimen, Pembrolizumab+MK-0482. No. of arms increased from 2 to 3 with increase in no. of patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top